Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
136.2 USD | +4.05% | +5.35% | +35.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.75% | 12.37B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+5.33% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+310.48% | 8.43B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta says its experimental Duchenne drug more effective than older medicine